Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBITDA: 2010-2024

Historic EBITDA for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$4.9 million.

  • China Pharma Holdings' EBITDA rose 39.39% to -$594,147 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 27.27%. This contributed to the annual value of -$4.9 million for FY2024, which is 52.16% down from last year.
  • Latest data reveals that China Pharma Holdings reported EBITDA of -$4.9 million as of FY2024, which was down 52.16% from -$3.2 million recorded in FY2023.
  • China Pharma Holdings' EBITDA's 5-year high stood at -$2.1 million during FY2020, with a 5-year trough of -$5.0 million in FY2022.
  • Moreover, its 3-year median value for EBITDA was -$4.9 million (2024), whereas its average is -$4.3 million.
  • Per our database at Business Quant, China Pharma Holdings' EBITDA skyrocketed by 89.74% in 2020 and then slumped by 56.03% in 2022.
  • Over the past 5 years, China Pharma Holdings' EBITDA (Yearly) stood at -$2.1 million in 2020, then plummeted by 51.66% to -$3.2 million in 2021, then slumped by 56.03% to -$5.0 million in 2022, then spiked by 35.53% to -$3.2 million in 2023, then tumbled by 52.16% to -$4.9 million in 2024.